27 reports of this reaction
2.0% of all AMINOCAPROIC ACID reports
#7 most reported adverse reaction
HAEMARTHROSIS is the #7 most commonly reported adverse reaction for AMINOCAPROIC ACID, manufactured by American Regent, Inc.. There are 27 FDA adverse event reports linking AMINOCAPROIC ACID to HAEMARTHROSIS. This represents approximately 2.0% of all 1,338 adverse event reports for this drug.
Patients taking AMINOCAPROIC ACID who experience haemarthrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMARTHROSIS is a less commonly reported adverse event for AMINOCAPROIC ACID, but still significant enough to appear in the safety profile.
In addition to haemarthrosis, the following adverse reactions have been reported for AMINOCAPROIC ACID:
The following drugs have also been linked to haemarthrosis in FDA adverse event reports:
HAEMARTHROSIS has been reported as an adverse event in 27 FDA reports for AMINOCAPROIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMARTHROSIS accounts for approximately 2.0% of all adverse event reports for AMINOCAPROIC ACID, making it a notable side effect.
If you experience haemarthrosis while taking AMINOCAPROIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.